• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    PCI Pharma Services

    Aphena Pharma Solutions

    Syngene

    test company saurabh
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Baxter BioPharma Solutions

    Alcami

    Adare Pharma Solutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine

    Expect to produce globally up to 50 million doses in 2020, up to 1.3 billion doses by the end of 2021; ready to distribute within hours after authorization.

    Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine
    BNT162b2 demonstrated a vaccine efficacy rate of 95%, with no serious safety concerns observed to date.
    Related CONTENT
    • Vetter continues its successful performance at the 2021 CMO Leadership Awards
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    • Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    • Anova Enterprises Acquires Corlexia Clinical Services
    Contract Pharma Staff11.20.20
    Pfizer and BioNTech have announced they will submit a request today to the U.S. FDA for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. 
     
    The submission is based on a vaccine efficacy rate of 95% demonstrated in the companies’ Phase 3 clinical study in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis was based on 170 confirmed cases of COVID-19. This submission is also supported by solicited safety data from a randomized subset of approximately 8,000 participants ≥18 years of age and unsolicited safety data from approximately 38,000 trial participants who have been followed for a median of two months following the second dose. The submission also includes solicited safety data on approximately 100 children 12-15 years of age. Approximately 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. To date, the Data Monitoring Committee (DMC) for the study has not reported any serious safety concerns related to the vaccine.
     
    “Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally. Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible.”
     
    Ugur Sahin, M.D., CEO and Co-founder of BioNTech, said, “Filing for Emergency Use Authorization in the U.S. is a critical step in making our vaccine candidate available to the global population as quickly as possible. We intend to continue to work with regulatory agencies worldwide to enable the rapid distribution of our vaccine globally. As a company located in Germany in the heart of Europe, our interactions with the European Medicines Agency are of particular importance to us and we have continuously provided data to them as part of our rolling review process.”
     
    The companies have already initiated rolling submissions with several regulatory agencies around the world, including the European Medicines Agency (EMA) and the Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK, and intend to submit applications to other regulatory agencies worldwide in the coming days. In some cases, governments may have regulatory pathways similar to an EUA. The companies will be ready to distribute the vaccine candidate within hours after authorization.
      
    The BNT162b2 vaccine candidate is not currently approved for distribution anywhere in the world. Both collaborators are committed to developing this novel vaccine with preclinical and clinical data at the forefront of all their decision making.
     
    Manufacturing and Delivery Capabilities
     
    While Pfizer and BioNTech await potential authorization or approval from regulatory agencies, the companies continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to authorization or approval, to help ensure it can reach those most in need as quickly as possible.
     
    Pfizer is bringing its leading in-house manufacturing capabilities to this effort, with the ability and experience to quickly scale, manufacture and distribute large quantities of vaccine at high quality, leveraging multiple sites in the U.S. and Europe, and complementing the mRNA manufacturing expertise of BioNTech, gained over almost a decade. Pfizer and BioNTech’s combined manufacturing network has the potential to supply up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses by the end of 2021 (subject to clinical success, manufacturing capacity, and regulatory approval or authorization).
     
    Pfizer has vast experience and expertise in cold-chain shipping and has an established infrastructure to supply the vaccine worldwide, including distribution hubs that can store vaccine doses for up to six months. The company has developed specially designed, temperature-controlled shippers for the BNT162b2 vaccine candidate, which can maintain recommended storage conditions (-70°C ±10°C) up to 15 days. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment. Once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2 - 8°C) conditions.
     
    From the start of the research program earlier this year, Pfizer and BioNTech have successfully supplied and distributed their investigational vaccine to more than 150 clinical trial sites across the U.S., as well as Europe, Latin America, and South Africa. Based on their collective experience, the companies believe in their capability to distribute the vaccine globally upon approval or authorization.
     
    About the Study
     
    The Phase 3 clinical trial of BNT162b2, which is based on BioNTech’s proprietary mRNA technology, began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate or placebo as of November 13, 2020. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in the U.S., Germany, Turkey, South Africa, Brazil and Argentina. Participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.
     
    Pfizer and BioNTech plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed.
    Related Searches
    • Clinical Trials
    • Biologics, Proteins, Vaccines
    Suggested For You
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    Anova Enterprises Acquires Corlexia Clinical Services Anova Enterprises Acquires Corlexia Clinical Services
    Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement
    UK Secures 40M Doses of Valneva COVID-19 Vax UK Secures 40M Doses of Valneva COVID-19 Vax
    Recipharm, Medspray Launch Resyca JV Recipharm, Medspray Launch Resyca JV
    Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership
    Delivering Custom Client Solutions Delivering Custom Client Solutions
    500+ Sites Join Inato’s Industry Marketplace 500+ Sites Join Inato’s Industry Marketplace
    PromoCell Receives EXCiPACT Certification PromoCell Receives EXCiPACT Certification
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Related Breaking News

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
      AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

      AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

      Joins network of approved manufacturers of lipid excipients for Pfizer-BioNTech COVID-19 vaccine.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.
      Kristin Brooks 02.24.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Facilities | Industry News
      Catalent Acquires Delphi Genetics

      Catalent Acquires Delphi Genetics

      Launches US plasmid manufacturing site to establish global pDNA development and manufacturing capabilities.
      Tim Wright, Editor, Contract Pharma 02.23.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      Avid Bioservices Begins Phase 2 of Myford Mfg. Expansion

      Avid Bioservices Begins Phase 2 of Myford Mfg. Expansion

      Build to include second manufacturing train with both upstream and downstream processing suites.
      Kristin Brooks 02.22.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News | Scale-up/Technology Transfer
      MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement

      MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement

      Minaris will provide GMP manufacturing, freezing and shipping of the MVX-ONCO-2 capsules from its site near Munich, Germany.
      Kristin Brooks 02.22.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
      G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing

      G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing

      Successfully completes the project within the client’s required schedule.
      Charles Sternberg, Assistant Editor 02.19.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
      Intravacc Unveils New Pilot Vaccine Production Facility

      Intravacc Unveils New Pilot Vaccine Production Facility

      State-of-the-art pilot plant for production of vaccine candidates in clinical phase I & II research.
      Tim Wright, Editor, Contract Pharma 02.19.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
      Century Therapeutics Significantly Expands Capabilities

      Century Therapeutics Significantly Expands Capabilities

      Unveils new operational, laboratory and manufacturing facilities in Pennsylvania and New Jersey.
      Tim Wright, Editor, Contract Pharma 02.19.21

    • Bio News | Breaking News | cGMP Manufacture | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
      RedHill and Cosmo Strengthen Manufacturing Agreements

      RedHill and Cosmo Strengthen Manufacturing Agreements

      Secures manufacturing capacity of Movantik for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.
      Tim Wright, Editor, Contract Pharma 02.19.21


    • Breaking News | Clinical Trials | CRO News
      PPD Awarded US Army RPA Develop PTSD Drugs

      PPD Awarded US Army RPA Develop PTSD Drugs

      Adaptive platform clinical research trial design aims to expedite potential new treatments for veterans.
      Kristin Brooks 02.18.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
      Pfizer, BioNTech To Supply 200M More Vax Doses to EU

      Pfizer, BioNTech To Supply 200M More Vax Doses to EU

      New agreement brings total supply to the European Union to 500 million doses, with delivery expected by the end of 2021.
      Charles Sternberg, Assistant Editor 02.17.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
      Novavax, SK Bioscience Expand Vax Pact

      Novavax, SK Bioscience Expand Vax Pact

      The existing partnership for manufacture of NVX-CoV2373 has been expanded to increase production capacity and supply vaccines to the Korean Government.
      Charles Sternberg, Assistant Editor 02.17.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
      Charles River Acquires CDMO Cognate BioServices

      Charles River Acquires CDMO Cognate BioServices

      Pays roughly $875 million to significantly expand capabilities in the cell and gene therapy sector.
      Tim Wright, Editor, Contract Pharma 02.17.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
      Kaneka Eurogentec Expands Capabilities

      Kaneka Eurogentec Expands Capabilities

      Receives GMP accreditation for new mRNA manufacturing facility, COVID-19 vaccine production ongoing.
      Tim Wright, Editor, Contract Pharma 02.17.21

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
      Biomunex, Onward Ink Strategic Antibody Development Pact

      Biomunex, Onward Ink Strategic Antibody Development Pact

      Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.
      Kristin Brooks 02.16.21

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers
    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Coatings World

    Latest Breaking News From Coatings World

    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Inahsi Naturals Achieves EU Compliance
    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Happi

    Latest Breaking News From Happi

    Clean Beauty Collective Supports EarthDay.org
    Freckle Pens Are Spot On!
    The Detox Market Partners with Good Face Project
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UFlex adds capacity in packaging films
    CEC expands into labels and packaging with Heidelberg
    ABG delivers Digicon Series 3 to UK printer
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login